943 C > T) and loss of the wild-type allele of LATS1 indicating biallelic disruption within LATS1. Even more important, they compared the LATS1 sequences between the superficial and infiltrative BCC and found no nucleotide alterations in the superficial BCC which showed the involvement of the Hippo pathway in BCC progression, highlighting another possible therapeutic target [24,37,38]. The gene discussed is LATS1; the disease is skin basal cell carcinoma.